Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $70,725.60 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Christopher Horan sold 10,340 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $6.84, for a total transaction of $70,725.60. Following the completion of the sale, the insider directly owned 312,744 shares in the company, valued at approximately $2,139,168.96. This trade represents a 3.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Up 2.0%

Artiva Biotherapeutics stock traded up $0.14 during trading on Tuesday, reaching $7.27. The stock had a trading volume of 664,480 shares, compared to its average volume of 393,650. Artiva Biotherapeutics, Inc. has a 52-week low of $2.71 and a 52-week high of $14.53. The stock has a market cap of $355.43 million, a PE ratio of -2.20 and a beta of 2.40. The business has a 50 day moving average price of $10.09 and a 200 day moving average price of $9.22.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting analysts’ consensus estimates of ($0.63). On average, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ARTV. Needham & Company LLC restated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $6,739,000. ADAR1 Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $1,151,000. Nantahala Capital Management LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $2,910,000. Alyeska Investment Group L.P. grew its stake in Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after buying an additional 173,615 shares during the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in Artiva Biotherapeutics during the second quarter worth approximately $8,483,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.